Search

Displaying results 2701 - 2710 of 4234 in total
  1. Drug

    Propoxycaine

    go.drugbank.com/drugs/DB09342
    Approved

    This drug was removed from the US market in 1996.

  2. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    Although not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary

  3. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

  4. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

  5. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.

  6. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].

  7. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). … Also known as the ileal bile acid transporter (IBAT), ASBT is primarily responsible for the enterohepatic recirculation of bile acids and ultimately for hepatic lipid and glucose metabolism [A32120].

  8. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    It was synthesized in the late 1970s and developed as a potential treatment for depression. … [A19824] Vanoxerine was later evaluated as a potential treatment for cocaine addiction due to its ability to block dopamine reuptake with a slower dissociation rate than cocaine.

  9. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.

  10. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine